Wedbush reiterated their outperform rating on shares of Fate Therapeutics (NASDAQ:FATE) in a research note published on Thursday, January 18th. The brokerage currently has a $7.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $10.00.
Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Fate Therapeutics from a hold rating to a buy rating and set a $7.50 price target on the stock in a research report on Tuesday, January 9th. HC Wainwright reaffirmed a buy rating and set a $7.00 price target on shares of Fate Therapeutics in a research report on Thursday, October 12th. Raymond James Financial reaffirmed a buy rating on shares of Fate Therapeutics in a research report on Tuesday, December 12th. BMO Capital Markets reaffirmed a buy rating and set a $7.00 price target on shares of Fate Therapeutics in a research report on Thursday, November 2nd. Finally, ValuEngine upgraded shares of Fate Therapeutics from a sell rating to a hold rating in a research note on Sunday, December 31st. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Buy and an average target price of $7.71.
Shares of Fate Therapeutics (NASDAQ FATE) traded up $0.05 on Thursday, hitting $7.85. 277,708 shares of the stock traded hands, compared to its average volume of 622,997. Fate Therapeutics has a 52 week low of $2.52 and a 52 week high of $9.78. The company has a market capitalization of $393.58, a price-to-earnings ratio of -8.26 and a beta of 2.00. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.21 and a quick ratio of 7.21.
WARNING: This piece of content was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://weekherald.com/2018/02/13/fate-therapeutics-fate-earns-outperform-rating-from-wedbush-2.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.